A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
British Journal of Dermatology2016Vol. 175(2), pp. 273–286
Citations Over TimeTop 1% of 2016 papers
Kim Papp, Kristian Reich, C. Paul, Andrew Blauvelt, Wojciech Baran, Chantal Bolduc, D. Toth, Richard G. Langley, Jennifer Clay Cather, Alice B. Gottlieb, Diamant Thaçi, James G. Krueger, Chris B. Russell, C.E. Milmont, Jing Li, Paul Klekotka, Greg Kricorian, Ajay Nirula
Abstract
Brodalumab therapy resulted in significant clinical benefit and an acceptable safety profile in patients with moderate-to-severe plaque psoriasis.
Related Papers
- → PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis(2016)14 cited
- → PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis(2017)1 cited
- W jaki sposób miarodajnie oceniać nasilenie łuszczycy(2016)
- 건선 환자에서 Cyclosporine 치료 효과와 관련된 인자에 대한 후향적 연구(2021)